Sini Heinonen1, Maheswary Muniandy1, Jana Buzkova2, Adil Mardinoglu3,4, Amaia Rodríguez5,6, Gema Frühbeck5,6, Antti Hakkarainen7, Jesper Lundbom7,8, Nina Lundbom7, Jaakko Kaprio9,10,11, Aila Rissanen1,12, Kirsi H Pietiläinen13,14,15. 1. Obesity Research Unit, Research Programs Unit, Diabetes and Obesity, University of Helsinki, Biomedicum Helsinki, C424b, P.O. Box 63, Haartmaninkatu 8, 00014, Helsinki, Finland. 2. Research Programs Unit, Molecular Neurology, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland. 3. Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden. 4. Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden. 5. Metabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain. 6. CIBEROBN, Instituto de Salud Carlos III, Pamplona, Spain. 7. HUS Medical Imaging Center, Radiology, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland. 8. Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research, Heinrich Heine University, Düsseldorf, Germany. 9. FIMM, Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland. 10. Finnish Twin Cohort Study, Department of Public Health, University of Helsinki, Helsinki, Finland. 11. National Institute for Health and Welfare, Department of Health, Helsinki, Finland. 12. Department of Psychiatry, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland. 13. Obesity Research Unit, Research Programs Unit, Diabetes and Obesity, University of Helsinki, Biomedicum Helsinki, C424b, P.O. Box 63, Haartmaninkatu 8, 00014, Helsinki, Finland. kirsi.pietilainen@helsinki.fi. 14. FIMM, Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland. kirsi.pietilainen@helsinki.fi. 15. Endocrinology, Abdominal Center, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland. kirsi.pietilainen@helsinki.fi.
Abstract
AIMS/HYPOTHESIS: Low mitochondrial activity in adipose tissue is suggested to be an underlying factor in obesity and its metabolic complications. We aimed to find out whether mitochondrial measures are downregulated in obesity also in isolated adipocytes. METHODS: We studied young adult monozygotic (MZ) twin pairs discordant (n = 14, intrapair difference ΔBMI ≥ 3 kg/m2) and concordant (n = 5, ΔBMI < 3 kg/m2) for BMI, identified from ten birth cohorts of 22- to 36-year-old Finnish twins. Abdominal body fat distribution (MRI), liver fat content (magnetic resonance spectroscopy), insulin sensitivity (OGTT), high-sensitivity C-reactive protein, serum lipids and adipokines were measured. Subcutaneous abdominal adipose tissue biopsies were obtained to analyse the transcriptomics patterns of the isolated adipocytes as well as of the whole adipose tissue. Mitochondrial DNA transcript levels in adipocytes were measured by quantitative real-time PCR. Western blots of oxidative phosphorylation (OXPHOS) protein levels in adipocytes were performed in obese and lean unrelated individuals. RESULTS: The heavier (BMI 29.9 ± 1.0 kg/m2) co-twins of the discordant twin pairs had more subcutaneous, intra-abdominal and liver fat and were more insulin resistant (p < 0.01 for all measures) than the lighter (24.1 ± 0.9 kg/m2) co-twins. Altogether, 2538 genes in adipocytes and 2135 in adipose tissue were significantly differentially expressed (nominal p < 0.05) between the co-twins. Pathway analysis of these transcripts in both isolated adipocytes and adipose tissue revealed that the heavier co-twins displayed reduced expression of genes relating to mitochondrial pathways, a result that was replicated when analysing the pathways behind the most consistently downregulated genes in the heavier co-twins (in at least 12 out of 14 pairs). Consistently upregulated genes in adipocytes were related to inflammation. We confirmed that mitochondrial DNA transcript levels (12S RNA, 16S RNA, COX1, ND5, CYTB), expression of mitochondrial ribosomal protein transcripts and a major mitochondrial regulator PGC-1α (also known as PPARGC1A) were reduced in the heavier co-twins' adipocytes (p < 0.05). OXPHOS protein levels of complexes I and III in adipocytes were lower in obese than in lean individuals. CONCLUSIONS/ INTERPRETATION: Subcutaneous abdominal adipocytes in obesity show global expressional downregulation of oxidative pathways, mitochondrial transcripts and OXPHOS protein levels and upregulation of inflammatory pathways. DATA AVAILABILITY: The datasets analysed and generated during the current study are available in the figshare repository, https://dx.doi.org/10.6084/m9.figshare.3806286.v1.
AIMS/HYPOTHESIS: Low mitochondrial activity in adipose tissue is suggested to be an underlying factor in obesity and its metabolic complications. We aimed to find out whether mitochondrial measures are downregulated in obesity also in isolated adipocytes. METHODS: We studied young adult monozygotic (MZ) twin pairs discordant (n = 14, intrapair difference ΔBMI ≥ 3 kg/m2) and concordant (n = 5, ΔBMI < 3 kg/m2) for BMI, identified from ten birth cohorts of 22- to 36-year-old Finnish twins. Abdominal body fat distribution (MRI), liver fat content (magnetic resonance spectroscopy), insulin sensitivity (OGTT), high-sensitivity C-reactive protein, serum lipids and adipokines were measured. Subcutaneous abdominal adipose tissue biopsies were obtained to analyse the transcriptomics patterns of the isolated adipocytes as well as of the whole adipose tissue. Mitochondrial DNA transcript levels in adipocytes were measured by quantitative real-time PCR. Western blots of oxidative phosphorylation (OXPHOS) protein levels in adipocytes were performed in obese and lean unrelated individuals. RESULTS: The heavier (BMI 29.9 ± 1.0 kg/m2) co-twins of the discordant twin pairs had more subcutaneous, intra-abdominal and liver fat and were more insulin resistant (p < 0.01 for all measures) than the lighter (24.1 ± 0.9 kg/m2) co-twins. Altogether, 2538 genes in adipocytes and 2135 in adipose tissue were significantly differentially expressed (nominal p < 0.05) between the co-twins. Pathway analysis of these transcripts in both isolated adipocytes and adipose tissue revealed that the heavier co-twins displayed reduced expression of genes relating to mitochondrial pathways, a result that was replicated when analysing the pathways behind the most consistently downregulated genes in the heavier co-twins (in at least 12 out of 14 pairs). Consistently upregulated genes in adipocytes were related to inflammation. We confirmed that mitochondrial DNA transcript levels (12S RNA, 16S RNA, COX1, ND5, CYTB), expression of mitochondrial ribosomal protein transcripts and a major mitochondrial regulator PGC-1α (also known as PPARGC1A) were reduced in the heavier co-twins' adipocytes (p < 0.05). OXPHOS protein levels of complexes I and III in adipocytes were lower in obese than in lean individuals. CONCLUSIONS/ INTERPRETATION: Subcutaneous abdominal adipocytes in obesity show global expressional downregulation of oxidative pathways, mitochondrial transcripts and OXPHOS protein levels and upregulation of inflammatory pathways. DATA AVAILABILITY: The datasets analysed and generated during the current study are available in the figshare repository, https://dx.doi.org/10.6084/m9.figshare.3806286.v1.
Authors: Ingrid Dahlman; Margaretha Forsgren; Annelie Sjögren; Elisabet Arvidsson Nordström; Maria Kaaman; Erik Näslund; Anneli Attersand; Peter Arner Journal: Diabetes Date: 2006-06 Impact factor: 9.461
Authors: R K Semple; V C Crowley; C P Sewter; M Laudes; C Christodoulides; R V Considine; A Vidal-Puig; S O'Rahilly Journal: Int J Obes Relat Metab Disord Date: 2004-01
Authors: David J Pagliarini; Sarah E Calvo; Betty Chang; Sunil A Sheth; Scott B Vafai; Shao-En Ong; Geoffrey A Walford; Canny Sugiana; Avihu Boneh; William K Chen; David E Hill; Marc Vidal; James G Evans; David R Thorburn; Steven A Carr; Vamsi K Mootha Journal: Cell Date: 2008-07-11 Impact factor: 41.582
Authors: J Naukkarinen; S Heinonen; A Hakkarainen; J Lundbom; K Vuolteenaho; L Saarinen; S Hautaniemi; A Rodriguez; G Frühbeck; P Pajunen; T Hyötyläinen; M Orešič; E Moilanen; A Suomalainen; N Lundbom; J Kaprio; A Rissanen; K H Pietiläinen Journal: Diabetologia Date: 2013-10-08 Impact factor: 10.122
Authors: Xiao Yin; Ian R Lanza; James M Swain; Michael G Sarr; K Sreekumaran Nair; Michael D Jensen Journal: J Clin Endocrinol Metab Date: 2013-11-25 Impact factor: 5.958
Authors: Justin A Fletcher; Melissa A Linden; Ryan D Sheldon; Grace M Meers; E Matthew Morris; Anthony Butterfield; James W Perfield; R Scott Rector; John P Thyfault Journal: Exp Physiol Date: 2018-01-16 Impact factor: 2.969
Authors: M T Kaartinen; M Arora; S Heinonen; A Hang; A Barry; J Lundbom; A Hakkarainen; N Lundholm; A Rissanen; J Kaprio; K H Pietiläinen Journal: Int J Obes (Lond) Date: 2020-11-21 Impact factor: 5.095
Authors: Zhenqi Zhou; Timothy M Moore; Brian G Drew; Vicent Ribas; Jonathan Wanagat; Mete Civelek; Mayuko Segawa; Dane M Wolf; Frode Norheim; Marcus M Seldin; Alexander R Strumwasser; Kate A Whitney; Ellen Lester; Britany R Reddish; Laurent Vergnes; Karen Reue; Prashant Rajbhandari; Peter Tontonoz; Jason Lee; Sushil K Mahata; Sylvia C Hewitt; Orian Shirihai; Craig Gastonbury; Kerrin S Small; Markku Laakso; Jorgen Jensen; Sindre Lee; Christian A Drevon; Kenneth S Korach; Aldons J Lusis; Andrea L Hevener Journal: Sci Transl Med Date: 2020-08-05 Impact factor: 19.319